Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2006-07-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01692145
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
NCT06927375
Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
NCT03383276
A Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01211951
Steroids for Corneal Ulcers Trial
NCT00324168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mw.
Administration of immunomodulator Mw.
Mycobacterium w.(Mw)-freeze dried extract 0.5ml
0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mycobacterium w.(Mw)-freeze dried extract 0.5ml
0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Associated Systemic disease
* Prior treatment received
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sudhalkar Eye Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aditya Sudhalkar
Dr. Aditya Sudhalkar
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bakulesh M Khamar, M.S. Ophthalmology
Role: PRINCIPAL_INVESTIGATOR
Thakore Eye Hospital, Ahmedabad
Mayuri B Khamar, M.S.Ophthalmology
Role: PRINCIPAL_INVESTIGATOR
M & J Institute Of Ophthalmology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sudhalkar Eye Hospital
Vadodara, Gujarat, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21234EH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.